Board Certified Cardiology Pharmacist (BCCP) Practice Exam 2026 - Free Cardiology Pharmacist Practice Questions and Study Guide

In a patient with significant atherosclerotic cardiovascular disease (ASCVD) risk, engaging in shared decision-making about whether to initiate moderate to high-intensity statin therapy is a critical approach. The rationale for this recommendation stems from the understanding that statins are most effective in reducing cardiovascular events and mortality in individuals who have a high risk for these outcomes.

Shared decision-making is essential as it involves discussing the benefits, risks, and patient preferences regarding treatment options. Patients with significant ASCVD risk are often in a position where moderate to high-intensity statin therapy can lead to substantial reductions in LDL cholesterol levels, which is associated with a decreased risk of future cardiovascular events. This process ensures that the patient understands their risk profile and the important role that statins can play in their treatment plan.

Additionally, initiating moderate to high-intensity statin therapy reflects current clinical guidelines, which advocate for aggressive lipid management in high-risk populations due to the proven efficacy of statins in reducing morbidity and mortality in these patients. By prioritizing patient involvement in the decision-making process, healthcare providers can enhance adherence and ultimately improve health outcomes.

The other options suggest delaying decisions or considering additional risk markers before statin initiation, which may not be necessary for patients already identified as having